GENEVA, Oct. 30 -- JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. filed a patent application (CN2026/092489) for “USE OF ANTI-NECTIN-4 ANTIBODY-DRUG CONJUGATE IN TREATMENT OF TUMORS”. With publication no. WO/2026/223742, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 47/68
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....